Bright Minds Biosciences (XCNQ:DRUG) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Days Payable?

Bright Minds Biosciences's average Accounts Payable for the three months ended in Dec. 2023 was C$0.49 Mil. Bright Minds Biosciences's Cost of Goods Sold for the three months ended in Dec. 2023 was C$0.00 Mil.

The historical rank and industry rank for Bright Minds Biosciences's Days Payable or its related term are showing as below:

XCNQ:DRUG's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.17
* Ranked among companies with meaningful Days Payable only.

Bright Minds Biosciences's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Bright Minds Biosciences Days Payable Historical Data

The historical data trend for Bright Minds Biosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Days Payable Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Days Payable

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Bright Minds Biosciences's Days Payable

For the Biotechnology subindustry, Bright Minds Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Days Payable falls into.

Bright Minds Biosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Bright Minds Biosciences's Days Payable for the fiscal year that ended in Sep. 2023 is calculated as

	Days Payable (A: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Sep. 2022 )	+	Accounts Payable (A: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (A: Sep. 2023 )	*	Days in Period
=	( (1.246	+	0.182)	/	2 )	/	0	*	365
=	0.714					/	0	*	365
=	N/A

Bright Minds Biosciences's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.182	+	0.8)	/	2 )	/	0	*	365 / 4
=	0.491					/	0	*	365 / 4
=	N/A

Bright Minds Biosciences Days Payable Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (XCNQ:DRUG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

DRUG:USA

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Executives

Jeremy Fryzuk

Director